These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36816933)

  • 1. Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma.
    Guo W; Zhu Y; Pu X; Guo H; Gan W
    Front Oncol; 2023; 13():1116648. PubMed ID: 36816933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
    Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
    Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
    Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xp11.2 Translocation Renal Cell Carcinoma With
    Ge Y; Lin X; Zhang Q; Lin D; Luo L; Wang H; Li Z
    Front Oncol; 2021; 11():784993. PubMed ID: 34917511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
    Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
    Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
    Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
    Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
    Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
    J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
    Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
    Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Heterogeneity of Xp11.2 Translocation Renal Cell Carcinoma: The Correlation Between Split Signal Pattern in FISH and Prognosis.
    Zhu Y; Pu X; Dong X; Ji C; Guo H; Li D; Zhao X; Gan W
    Cancer Manag Res; 2021; 13():2419-2431. PubMed ID: 33758541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.
    Just PA; Letourneur F; Pouliquen C; Dome F; Audebourg A; Biquet P; Vidaud M; Terris B; Sibony M; Pasmant E
    Genes Chromosomes Cancer; 2016 Jun; 55(6):541-8. PubMed ID: 26998913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
    Classe M; Malouf GG; Su X; Yao H; Thompson EJ; Doss DJ; Grégoire V; Lenobin J; Fantoni JC; Sudour-Bonnange H; Khayat D; Aubert S; Tannir NM; Leroy X
    Histopathology; 2017 Jun; 70(7):1089-1097. PubMed ID: 28106924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population.
    Qu Y; Gu C; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
    Sci Rep; 2016 Feb; 6():21677. PubMed ID: 26880493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
    Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
    Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
    Xu ZY; Wang JP; Zhang Y; Wu SW; Ma L; Qin YZ; Wang ZP; Chai DM; Tao YS
    Am J Transl Res; 2019; 11(1):327-339. PubMed ID: 30787990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
    Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
    Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.